NEW YORK, December 19, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Endo Health Solutions Inc. (NASDAQ: ENDP), HCA Holdings, Inc. (NYSE: HCA), Covidien plc (NYSE: COV), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), and Seattle Genetics Inc. (NASDAQ: SGEN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endo Health Solutions Inc. Research Report
On December 11, 2013, Endo Health Solutions Inc. (Endo) announced that its wholly-owned subsidiary, Endo Finance Co., has priced $700 million aggregate principal amount of 5.75% senior unsecured notes due January 2022 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering. Endo intends to use the net proceeds from the offering, together with borrowings under the term loan portion of a new senior secured credit facility, to refinance its existing senior secured credit facility, to pay related fees and expenses and for general corporate purposes, which may include strategic acquisitions. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
HCA Holdings, Inc. Research Report
On December 13, 2013, HCA Holdings, Inc. (HCA) and Florida Blue announced a contract renewal that ensures Florida Blue members will continue to have access to high quality care at HCA's 42 hospitals and 32 surgery centers throughout Florida. "HCA and Florida Blue share a commitment to providing high quality, high value care to Floridians," said Juan Vallarino, Senior Vice President of Employer and Payor Engagement, who leads managed care negotiations for HCA. "We're pleased to renew this agreement and continue to provide Florida Blue members access to the premier care HCA provides." The Full Research Report on HCA Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Covidien plc Research Report
On December 16, 2013, Covidien plc (Covidien) announced supplemental information and additional changes in connection with its revenue reporting format. According to the Company, the new format provides a worldwide view of sales across three major product categories while enhancing geographic reporting by breaking out non-U.S. sales into new categories for emerging and non-U.S. developed markets. The Company informed that it will begin using this format when it releases its Q1 FY 2014 results in January 2014. "Our new revenue reporting format more closely reflects the way we operate our business, providing our stakeholders with enhanced transparency," said Charles J. Dockendorff, Executive Vice President & Chief Financial Officer, Covidien. "This approach underscores our continuing commitment to communicating our business results clearly and consistently." Further, the Company reported that it continues to estimate net sales in FY 2014 will be up 2% to 5% YoY, while sales are expected to be up 3% to 6% YoY for Surgical Solutions; up 3% to 6% YoY for Vascular Therapies; and up 1% to 4% YoY for Respiratory & Patient Care. The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Vertex Pharmaceuticals Incorporated Research Report
On December 16, 2013, Vertex Pharmaceuticals Inc. (Vertex) stock declined 0.64% to end the day with $64.76. The Company's stock went down by 0.57% over the past three trading days, compared to the Dow Jones Industrial Average which went up by 0.26% during the same trading period. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Seattle Genetics Inc. Research Report
On December 10, 2013, Seattle Genetics, Inc. (Seattle Genetics) announced updated results from a phase 2 clinical trial of ADCETRIS (brentuximab vedotin) in diffuse large B-cell lymphoma (DLBCL) and other B-cell non-Hodgkin lymphomas. "In DLBCL, patients with relapsed or refractory disease have poor outcomes, and there is a significant need for better therapeutic approaches to treat this aggressive non-Hodgkin lymphoma subtype," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. "We are encouraged by the interim phase 2 results which demonstrated that single-agent ADCETRIS induced a 42 percent objective response rate and manageable safety profile among advanced DLBCL patients, including a high percentage whose disease was refractory to their prior therapy. Based on these data, we have expanded our clinical program for ADCETRIS in DLBCL both as a single-agent and in combination with standard regimens for both relapsed and newly diagnosed patients." The Full Research Report on Seattle Genetics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner